Abstract
Influence of imatinib as adjuvant therapy on relapse-free survival in patients with gastrointestinal stromal tumors at moderate to high risk of recurrence
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have